Differential hepatic activation of mouse and human peroxisome proliferator-activated receptor-α by perfluorohexane sulfonate
- PMID: 40036302
- PMCID: PMC12225666
- DOI: 10.1093/toxsci/kfaf026
Differential hepatic activation of mouse and human peroxisome proliferator-activated receptor-α by perfluorohexane sulfonate
Abstract
Exposure of perfluorohexane sulfonate (PFHxS) is associated with hepatomegaly and accumulation of lipids that may be mediated by nuclear receptors like peroxisome proliferator-activated receptor-α (PPARα), constitutive androstane receptor (CAR), or pregnane X receptor (PXR). This study tested the hypotheses that: (i) PFHxS causes changes in liver by activating PPARα, CAR, or PXR, and (ii) there is a species difference in PPARα activity by PFHxS. Wild-type, Ppara-null, and PPARA-humanized mice were fed either a control diet, or one containing 2.2 mg PFHxS/kg diet or 25.8 mg PFHxS/kg diet for either 7 or 28 days, and target gene expression was examined. Relative liver weights were similar after 7 days with either 2.2 or 25.8 mg PFHxS/kg dietary exposure compared with controls. Relative liver weights were higher after treatment for 28 days in all 3 genotypes fed 25.8 mg PFHxS/kg diet compared with controls. The concentration of PFHxS was dose-dependently increased in serum and liver compared with controls. PFHxS exposure of 2.2 and 25.8 mg PFHxS/kg diet caused an increase in expression of PPARα target genes in wild-type mice and this effect was not observed in similarly treated Ppara-null mice or PPARA-humanized mice. Administration of PFHxS caused increased expression of the CAR target gene Cyp2b10 in all 3 genotypes at both timepoints, and the PXR target gene Cyp3a11 in all 3 genotypes after 28 days. Exposure to PFHxS can increase liver weight due in part to the activation of mouse, but not human, PPARα. Activation of CAR and PXR by PFHxS also likely contributes to the observed hepatomegaly in all 3 genotypes.
Keywords: liver; perfluorohexane sulfonate; peroxisome proliferator-activated receptor-α; species difference.
© The Author(s) 2025. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Figures



References
-
- Bijland S, Rensen PC, Pieterman EJ, Maas AC, van der Hoorn JW, van Erk MJ, Havekes LM, Willems van Dijk K, Chang SC, Ehresman DJ, et al. 2011. Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE3-Leiden CETP mice. Toxicol Sci. 123:290–303. - PubMed
-
- Blystone CR, Dzierlenga AL, Herbert RA, Janardhan KS, Bouknight SA, Buccellato MA, Cora MC, Cristy TA, Cunny HC, DeVito MJ, et al. 2022. National Toxicology Program (NTP) technical report on the toxicity studies of perfluoroalkyl sulfonates (perfluorobutane sulfonic acid, perfluorohexane sulfonate potassium salt, and perfluorooctane sulfonic acid) administered by gavage to Sprague Dawley (Hsd: Sprague Dawley SD) rats (revised). Toxicity Report 96. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service.
-
- Butenhoff JL, Chang SC, Ehresman DJ, York RG. 2009. Evaluation of potential reproductive and developmental toxicity of potassium perfluorohexanesulfonate in Sprague Dawley rats. Reprod Toxicol. 27:331–341. - PubMed
-
- Chang S, Butenhoff JL, Parker GA, Coder PS, Zitzow JD, Krisko RM, Bjork JA, Wallace KB, Seed JG. 2018. Reproductive and developmental toxicity of potassium perfluorohexanesulfonate in CD-1 mice. Reprod Toxicol. 78:150–168. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources